THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)
THU0272 Epratuzumab Maintains Improvements in Disease Activity for Over 2 Years in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008)